Title	Antioxidant and antiproliferative activities of red pitaya
Author	Li-chen Wu, Hsiu-Wen Hsu, Yun-Chen Chen, Chih-Chung Chiu, Yu-In Lin and Ja-an Annie Ho
Citation	Food Chemistry Volume 95, Issue 2, March 2006, Pages 319-327
Keyword	Phenolics; Red pitaya; Polyphenols; Antioxidant activity; DPPH; ABTS ; B16F10 melanoma cells

Abstract

The red pitaya, rich in micronutrients, has recently generated a great deal of consumer interest, therefore, this paper was designed to study the total phenolic content, antioxidant activity and antiproliferative activity of red pitaya on melanoma cells and to determine if it is a valuable source of antioxidants and an anticancer agent. The total phenolic contents of flesh (42.4 ± 0.04 mg of gallic acid equivalents (GAE)/100 g of flesh fresh weight) and peel (39.7 ± 5.39 mg of GAE/100 g of peel fresh weight) were similar. The flavonoid contents of flesh and peel did not vary much (7.21 ± 0.02 mg vs. 8.33 ± 0.11 mg of catechin equivalents/100 g of flesh and peel matters). The concentrations of betacyanins expressed as betanin equivalents per 100 g of fresh flesh and peel were 10.3 ± 0.22 and 13.8 ± 0.85 mg, respectively. The antioxidant activity, measured by the DPPH• method at EC₅₀, was 22.4 ± 0.29 and $118 \pm 4.12 \mu$ mol vitamin C equivalents/g of flesh and peel dried extract; the values of EC₅₀, determined by the ABTS•⁺ approach, were 28.3 ± 0.83 and $175 \pm 15.7 \mu$ mol of trolox equivalents antioxidant capacity (TEAC)/g of flesh and peel dried extract, respectively. The antiproliferative study on B16F10 melanoma cells revealed that the peel (EC₅₀ 25.0 µg of peel matter) component was a stronger inhibitor of the growth of B16F10 melanoma cancer cells than the flesh. The results indicated that the flesh and peel were both rich in polyphenols and were good sources of antioxidants. The red pitaya peel fulfilled its promise to inhibit the growth of melanoma cells.

Abbreviations: GAE, Gallic acid equivalents; TEAC, Trolox equivalent antioxidant capacity; CHD, Coronary heart disease; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide